Novo Nordisk's latest marketcap:
As of 06/03/2026, Novo Nordisk's market capitalization has reached $191.64 B. According to our data, Novo Nordisk is the 100th most valuable company globally by market capitalization. Market capitalization, commonly referred to as market cap, represents the total market value of all outstanding shares of a publicly traded company and is often used as a measure of company value.
| Market Cap | 191.64 B |
| Revenue (ttm) | 50.57 B |
| Net Income (ttm) | 18.81 B |
| Shares Out | 4.44 B |
| EPS (ttm) | 4.23 |
| Forward PE | 13.65 |
| Ex-Dividend Date | 03/30/2026 |
| Earnings Date | 05/06/2026 |
Novo Nordisk's yearly market capitalization.
| Date | Market Cap($) | Change (%) | Global Rank |
|---|---|---|---|
| 06/03/2026 | $191.64 B | -9.98% | 100 |
| 12/31/2025 | $226.09 B | -41.72% | 25 |
| 12/31/2024 | $387.95 B | -17.76% | 23 |
| 12/29/2023 | $471.73 B | 54.12% | 16 |
| 12/30/2022 | $306.08 B | 19.24% | 26 |
| 12/31/2021 | $256.69 B | 55.86% | 40 |
| 12/31/2020 | $164.7 B | 16.14% | 66 |
| 12/31/2019 | $141.81 B | 23.12% | 62 |
| 12/31/2018 | $115.18 B | -15.84% | 63 |
| 12/29/2017 | $136.86 B | 46.79% | 56 |
Company Profile
About Novo Nordisk A/S
Novo Nordisk A/S, together with its subsidiaries, is a global pharmaceutical company specializing in research, development, manufacturing, and distribution. Headquartered in Bagsvaerd, Denmark, the company operates across Europe, the Middle East, Africa, North America, and Asia, including Mainland China, Hong Kong, and Taiwan.
Business Segments
- Diabetes and Obesity Care: Offers products for diabetes, obesity, cardiovascular diseases, and other emerging therapies.
- Rare Disease: Provides treatments for rare blood disorders, rare endocrine disorders, and hormone replacement therapy.
Key Products & Innovations
- Insulin pens, growth hormone pens, and injection needles.
- Smart diabetes solutions, including smart insulin pens and the Dose Check app for insulin dose guidance.
Strategic Collaborations
- Partnership with UNICEF to address childhood obesity.
- Collaboration with Valo Health, Inc. to develop novel cardiometabolic treatments.
Founded in 1923, Novo Nordisk A/S continues to be a leader in pharmaceutical innovation.
Frequently Asked Questions
-
What is Novo Nordisk's (NVO) current market cap?As of 06/03/2026, Novo Nordisk (including the parent company, if applicable) has an estimated market capitalization of $191.64 B USD. This figure represents the total market value of its outstanding shares, including different share classes. Please note that market capitalization fluctuates based on market conditions, and the actual valuation may differ from the latest estimate.
-
Where does Novo Nordisk (NVO) rank globally by market cap?Novo Nordisk global market capitalization ranking is approximately 100 as of 06/03/2026. This ranking is relative to all publicly traded companies worldwide and can fluctuate based on market dynamics and the performance of other companies. You can refer to our Global companies market cap ranking for the most up-to-date ranking.